What is it about?
Immunotherapy has revolutionalized cancer therapy. However, it is associated with a unique spectrum of immune-related adverse events which are treated with steroids. For individuals who do not respond to steroids, treatment options are limited. We have shown that steroid refractory immune-related adverse events can be successfully treated with Tocilizumab.
Featured Image
Why is it important?
As the indications for immunotherapy continue to expand, it becomes important to address the management of immune-related adverse events. For patients who do not respond to steroids, treatment options are limited. We have successfully utilized the anti- IL-6R antibody, Tocilizumab to abate steroid refractory immune-related adverse events.
Perspectives
Co-authoring this manuscript was very exciting. This comes at a time when several indications have emerged for immunotherapy but no randomized clinical trials exist for the management of immune-related toxicities. We have extrapolated the CART therapy experience of treating Cytokine Release Syndrome with Tocilizumab to treat immune-related adverse events. I hope that our findings will bring attention to the high incidence of clinically significant immune-related adverse events in the real world and provide a basis for future clinical trials.
Aparna Hegde
East Carolina University
Read the Original
This page is a summary of: Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade, Journal of Oncology Pharmacy Practice, December 2017, SAGE Publications,
DOI: 10.1177/1078155217745144.
You can read the full text:
Resources
Contributors
The following have contributed to this page
